Genomes.io is a genomic data security company co-founded by Dr Mark Hahnel and Aldo de Pape in 2018. We are a UK-registered company and we operate from London, UK.
The expectations of research organizations, institutions, and customers are increasing, and GenomesDAO is built from the ground up to meet those expectations.
In order to increase the democratization and decentralization of genomic studies, we focus on combining cutting-edge technologies such as AMD’s SEV, blockchain and decentralized finance.
Whole Genome Sequencing
- We work with trusted, industry leading DNA sequencing providers from around the globe to provide clinical quality (30x) whole genome sequencing for our users. This analyses 100% of your genome, giving you full ownership.
Secure Encrypted Data
- We harness secure encrypted virtualisation - encrypted state (SEV-ES) technology to create fully encrypted 'vaults' for user DNA data. This provides secure cloud storage of DNA data, owned and controlled by the user.
- We leverage the Ethereum blockchain to provide a transparent and immutable audit log of access to your genome. This means our users can be sure their DNA data is stored and shared in exactly the way they decide.
- We offer the general public access to clinical-grade, 30x whole genome sequencing, personalized genomic reports based on this data, and secure data storage in their personal DNA Vault. Using the Genomes mobile app, our users control third-party access to their DNA Vault by approving each query of their vault. Put simply, each query asks a question of your genome. The only information released is the answer to that question. This innovation allows vault holders to get paid for contributing data to research, without ever losing privacy or giving up ownership of their genome. Not only that but you also gain direct access to insights that your genome provides.
- We offer organisations our DNA Vault technology to create secure and participant-owned genomic databases. Genomes.io allows rare disease patient organisations, population sequencing initiatives, healthcare providers to contribute genomic data of their participants to drive research and innovation. This is done with a responsible model that ensures private and transparent data access, fully informed repeat consent, and equitable compensation.
- We offer researchers (e.g. biotech companies, academia) the ability to easily query databases of relevant and high quality genomic datasets. Researchers can use this to understand the causes of disease and to develop new drugs. In our model, genomic data can be made available to researchers to supercharge medical innovation, but without compromising the privacy or ownership rights of individuals.